- Previous Close
0.0000 - Open
-- - Bid 0.0001 x --
- Ask --
- Day's Range
-- - 52 Week Range
0.0020 - 0.2900 - Volume
-- - Avg. Volume
373 - Market Cap (intraday)
174.244M - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
dimerix.comRecent News: SBMJF
View More
Performance Overview: SBMJF
Trailing total returns as of 3/20/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBMJF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBMJF
View MoreValuation Measures
Market Cap
174.81M
Enterprise Value
161.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
30.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-79.26%
Return on Equity (ttm)
-524.69%
Revenue (ttm)
737.87k
Net Income Avi to Common (ttm)
-23.31M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
21.11M
Total Debt/Equity (mrq)
2.18%
Levered Free Cash Flow (ttm)
-10.23M
Company Insights: SBMJF
SBMJF does not have Company Insights